Retatrutide and semaglutide are both incretin-based peptides, but they sit at very different points on the regulatory map. Retatrutide is an investigational triple agonist targeting GLP-1, GIP, and glucagon receptors, while semaglutide is an FDA-approved GLP-1 agonist sold as Ozempic and Wegovy. The most important asymmetry is that one is approved with a product label and the other is not.
Reviewed for accuracy · Last reviewed July 7, 2026The clearest practical difference is regulatory. Semaglutide has an approved label, a defined titration, and Phase 3 evidence including the STEP 1 weight-management trial, whereas retatrutide is still investigational with no approved dose or long-term human safety record.
Mechanistically, retatrutide adds two receptor targets (GIP and glucagon) on top of the GLP-1 target semaglutide uses. Whether that translates into a meaningful real-world difference is not something the current evidence lets anyone state as fact, because retatrutide's human data comes from a single Phase 2 obesity trial.
Both were studied as once-weekly subcutaneous injections with gradual dose escalation, and both reported predominantly gastrointestinal side effects that were dose-related. Cross-trial comparisons between an investigational compound and an approved one are not a reliable ranking, and which, if either, is appropriate is a medical decision.
This page is an independent educational reference and is not medical advice, and does not indicate any approval status for any use. Talk to a doctor before starting any compound.